Key points are not available for this paper at this time.
The European Medicines Agency aims to make patient-level data from clinical trials publicly accessible while protecting privacy; this would improve drug-development efficiency, cost-effectiveness, and comparative-effectiveness analysis and reduce duplication of effort.
Eichler et al. (Mon,) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: